SE9703376D0 - A new combination - Google Patents

A new combination

Info

Publication number
SE9703376D0
SE9703376D0 SE9703376A SE9703376A SE9703376D0 SE 9703376 D0 SE9703376 D0 SE 9703376D0 SE 9703376 A SE9703376 A SE 9703376A SE 9703376 A SE9703376 A SE 9703376A SE 9703376 D0 SE9703376 D0 SE 9703376D0
Authority
SE
Sweden
Prior art keywords
combination
pct
alkyl
enantiomer
sec
Prior art date
Application number
SE9703376A
Other languages
English (en)
Inventor
Stefan Berg
Svante Ross
Seth-Olov Thorberg
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9703376A priority Critical patent/SE9703376D0/sv
Publication of SE9703376D0 publication Critical patent/SE9703376D0/sv
Priority to ZA987804A priority patent/ZA987804B/xx
Priority to SK283-2000A priority patent/SK2832000A3/sk
Priority to IDW20000522D priority patent/ID25789A/id
Priority to EEP200000146A priority patent/EE200000146A/xx
Priority to JP2000511500A priority patent/JP2001516719A/ja
Priority to CN98811114A priority patent/CN1278727A/zh
Priority to PCT/SE1998/001602 priority patent/WO1999013878A1/en
Priority to HU0100621A priority patent/HUP0100621A2/hu
Priority to AT98944376T priority patent/ATE270889T1/de
Priority to US09/171,578 priority patent/US6159970A/en
Priority to EP98944376A priority patent/EP1014986B1/en
Priority to KR1020007002835A priority patent/KR20010024087A/ko
Priority to IL13477598A priority patent/IL134775A0/xx
Priority to DK98944376T priority patent/DK1014986T3/da
Priority to TR2000/00725T priority patent/TR200000725T2/xx
Priority to CA002302204A priority patent/CA2302204A1/en
Priority to PT98944376T priority patent/PT1014986E/pt
Priority to BR9812236-3A priority patent/BR9812236A/pt
Priority to ES98944376T priority patent/ES2222603T3/es
Priority to PL98339368A priority patent/PL339368A1/xx
Priority to DE69825062T priority patent/DE69825062T2/de
Priority to KR1020007002830A priority patent/KR20010024084A/ko
Priority to MXPA00002616A priority patent/MXPA00002616A/es
Priority to AU91931/98A priority patent/AU752719B2/en
Priority to ARP980104635A priority patent/AR013503A1/es
Priority to IS5401A priority patent/IS5401A/is
Priority to NO20001400A priority patent/NO20001400L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE9703376A 1997-09-18 1997-09-18 A new combination SE9703376D0 (sv)

Priority Applications (28)

Application Number Priority Date Filing Date Title
SE9703376A SE9703376D0 (sv) 1997-09-18 1997-09-18 A new combination
ZA987804A ZA987804B (en) 1997-09-18 1998-08-27 A combination of a monoamine oxidase inhibitor and a H5-HT1b antagonists or agonist
AU91931/98A AU752719B2 (en) 1997-09-18 1998-09-09 A combination of a monoamine oxidase inhibitor and a h5-HT 1B antagonist or partial agonist
KR1020007002835A KR20010024087A (ko) 1997-09-18 1998-09-09 모노아민 옥시다제 억제제 및 ｈ5-ＨＴ1Ｂ 길항제 또는부분 작용제의 배합물
TR2000/00725T TR200000725T2 (tr) 1997-09-18 1998-09-09 Bir monoamin oksidaz inhibitörü ve h5-HT1B antagonistinin bileşimi
EEP200000146A EE200000146A (et) 1997-09-18 1998-09-09 Monoamiini oksüdaasi inhibiitori kombinatsioon h5-HT 1B antagonisti või osalise agonistiga
JP2000511500A JP2001516719A (ja) 1997-09-18 1998-09-09 モノアミンオキシダーゼ阻害剤およびｈ５−ＨＴ１Ｂアンタゴニストまたは部分的アゴニストの組み合わせ
CN98811114A CN1278727A (zh) 1997-09-18 1998-09-09 单胺氧化酶抑制剂和h5－ht1B拮抗剂或部分激动剂的组合
PCT/SE1998/001602 WO1999013878A1 (en) 1997-09-18 1998-09-09 A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST
HU0100621A HUP0100621A2 (hu) 1997-09-18 1998-09-09 Monoamin oxidáz inhibitor hatású vegyületek és h5-HT1B antagonista vagy részleges agonista hatású vegyületek kombinációját tartalmazó gyógyászati készítmények
AT98944376T ATE270889T1 (de) 1997-09-18 1998-09-09 Monoaminoxidase inhibitor- und h5-ht 1 beta antagonist oder partiellagonist enthaltende mischung
US09/171,578 US6159970A (en) 1997-09-18 1998-09-09 Combination of a monoamine oxidase inhibitor and a h5-HT1B antagonist or partial agonist
EP98944376A EP1014986B1 (en) 1997-09-18 1998-09-09 A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT 1 BETA ANTAGONIST OR PARTIAL AGONIST
SK283-2000A SK2832000A3 (en) 1997-09-18 1998-09-09 A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A H5-HT1Bì (54) ANTAGONIST OR PARTIAL AGONIST
IL13477598A IL134775A0 (en) 1997-09-18 1998-09-09 A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST
DK98944376T DK1014986T3 (da) 1997-09-18 1998-09-09 Kombination af en inhibitor for monoaminoxidase og en antagonist eller delvis agonist for h5-HT 1 beta
IDW20000522D ID25789A (id) 1997-09-18 1998-09-09 KOMBINASI DARI INHIBITOR MONOAMINA OKSIDASI DAN ANTAGONIS ATAU SEBAGIAN AGONIS h5-HT1B
CA002302204A CA2302204A1 (en) 1997-09-18 1998-09-09 A combination of a monoamine oxidase inhibitor and a h5-ht1b antagonist or partial agonist
PT98944376T PT1014986E (pt) 1997-09-18 1998-09-09 Uma combinacao de um inibidor da monoamino-oxidase e de um antagonista ou de umagonista parcial do h5-ht 1 beta
BR9812236-3A BR9812236A (pt) 1997-09-18 1998-09-09 Combinação de componentes, uso desta, processos para a preparação da mesma, para o tratamento de distúrbios afetivos, para o tratamento de depressão, e para melhorar o inìcio de ação terapêutica, formulação farmacêutica, e, kit
ES98944376T ES2222603T3 (es) 1997-09-18 1998-09-09 Una combinacion de un inhibidor de la monoamino-oxidasa y un antagonista o agonista parcial de h5-ht1 beta.
PL98339368A PL339368A1 (en) 1997-09-18 1998-09-09 Composition of monoamine oxidase inhibitor and antagonist or partial agonist of h5-ht 1b
DE69825062T DE69825062T2 (de) 1997-09-18 1998-09-09 Monoaminoxidase inhibitor- und h5-ht 1 beta antagonist oder partiellagonist enthaltende mischung
KR1020007002830A KR20010024084A (ko) 1997-09-18 1998-09-09 모노아민 옥시다제 억제제 및 ｈ5-ＨＴ1Ｂ 길항제 또는부분 작용제의 배합물
MXPA00002616A MXPA00002616A (es) 1997-09-18 1998-09-09 Combinacion de un inhibidor de la monoamina-oxidasa y un antagonista o agonista parcial de h5-ht1b.
ARP980104635A AR013503A1 (es) 1997-09-18 1998-09-17 Una combinacion de un inhibidor de la monoamina oxidasa y un antagonista o agonista parcial selectivo de h5-ht(1b), formulacion farmaceutica, usos ymetodo de preparacion
IS5401A IS5401A (is) 1997-09-18 2000-03-14 Samsetning mónóamínoxídasa hemils og h5-HT1B mótlyfs eða gerandefnis með hlutaverkun
NO20001400A NO20001400L (no) 1997-09-18 2000-03-17 Kombinasjon av en monoaminooksidaseinhibitor og en h5-HT1B antagonist eller partiell agonist

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9703376A SE9703376D0 (sv) 1997-09-18 1997-09-18 A new combination

Publications (1)

Publication Number Publication Date
SE9703376D0 true SE9703376D0 (sv) 1997-09-18

Family

ID=20408296

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9703376A SE9703376D0 (sv) 1997-09-18 1997-09-18 A new combination

Country Status (27)

Country Link
US (1) US6159970A (sv)
EP (1) EP1014986B1 (sv)
JP (1) JP2001516719A (sv)
KR (2) KR20010024084A (sv)
CN (1) CN1278727A (sv)
AR (1) AR013503A1 (sv)
AT (1) ATE270889T1 (sv)
AU (1) AU752719B2 (sv)
BR (1) BR9812236A (sv)
CA (1) CA2302204A1 (sv)
DE (1) DE69825062T2 (sv)
DK (1) DK1014986T3 (sv)
EE (1) EE200000146A (sv)
ES (1) ES2222603T3 (sv)
HU (1) HUP0100621A2 (sv)
ID (1) ID25789A (sv)
IL (1) IL134775A0 (sv)
IS (1) IS5401A (sv)
MX (1) MXPA00002616A (sv)
NO (1) NO20001400L (sv)
PL (1) PL339368A1 (sv)
PT (1) PT1014986E (sv)
SE (1) SE9703376D0 (sv)
SK (1) SK2832000A3 (sv)
TR (1) TR200000725T2 (sv)
WO (1) WO1999013878A1 (sv)
ZA (1) ZA987804B (sv)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957948A (en) * 1988-05-05 1990-09-18 Interface, Inc. Biocidal protective coating for heat exchanger coils
SE9601110D0 (sv) 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
WO2002066454A1 (en) * 2001-02-21 2002-08-29 Sankyo Company, Limited Chromene derivatives
DK1408976T5 (da) * 2001-07-20 2011-01-10 Psychogenics Inc Behandling af ADHD (Attention deficit hyperactivity disorder)
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
JP2009533325A (ja) * 2006-03-17 2009-09-17 アストラゼネカ・アクチエボラーグ ５−ｈｔ６調節剤としての新規なテトラリン
JP5379692B2 (ja) 2006-11-09 2013-12-25 プロビオドルグ エージー 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
SI2091948T1 (sl) 2006-11-30 2012-07-31 Probiodrug Ag Novi inhibitorji glutaminil ciklaze
NZ579310A (en) 2007-03-01 2012-03-30 Probiodrug Ag Use of glutaminyl cyclase inhibitors for the treatment of mild cognitive impairment and diagnostic purposes thereof
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
MX2012002993A (es) 2009-09-11 2012-04-19 Probiodrug Ag Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
SG183229A1 (en) 2010-03-10 2012-09-27 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
DK2686313T3 (en) 2011-03-16 2016-05-02 Probiodrug Ag Benzimidazole derivatives as inhibitors of glutaminyl cyclase
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
CN110179988A (zh) * 2019-07-10 2019-08-30 王大伟 五羟色胺再摄取抑制剂和单胺氧化酶抑制剂联合在制备治疗抑郁症或早泄药物中的应用
WO2024130044A1 (en) * 2022-12-14 2024-06-20 Luminous Mind Inc. Treatment of psychological factors affecting other medical conditions (pfaomc)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
ES2162792T3 (es) * 1991-09-18 2002-01-16 Glaxo Group Ltd Derivados de benzanilida como antagonistas de 5-ht1d.
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives

Also Published As

Publication number Publication date
ES2222603T3 (es) 2005-02-01
DE69825062D1 (de) 2004-08-19
AU752719B2 (en) 2002-09-26
IS5401A (is) 2000-03-14
CA2302204A1 (en) 1999-03-25
SK2832000A3 (en) 2000-09-12
EP1014986B1 (en) 2004-07-14
AR013503A1 (es) 2000-12-27
MXPA00002616A (es) 2002-04-24
NO20001400D0 (no) 2000-03-17
BR9812236A (pt) 2000-07-18
PL339368A1 (en) 2000-12-18
TR200000725T2 (tr) 2000-08-21
CN1278727A (zh) 2001-01-03
US6159970A (en) 2000-12-12
HUP0100621A2 (hu) 2001-08-28
PT1014986E (pt) 2004-10-29
EP1014986A1 (en) 2000-07-05
ZA987804B (en) 1999-03-18
ID25789A (id) 2000-11-02
EE200000146A (et) 2001-02-15
DE69825062T2 (de) 2005-08-25
WO1999013878A1 (en) 1999-03-25
IL134775A0 (en) 2001-04-30
AU9193198A (en) 1999-04-05
JP2001516719A (ja) 2001-10-02
KR20010024087A (ko) 2001-03-26
ATE270889T1 (de) 2004-07-15
NO20001400L (no) 2000-05-05
KR20010024084A (ko) 2001-03-26
DK1014986T3 (da) 2004-10-25

Similar Documents

Publication Publication Date Title
SE9703375D0 (sv) A new combination
SE9703376D0 (sv) A new combination
DK0794949T3 (da) Hidtil ukendte 3,5-dioxo-(2H,4H)-1,2,4-triazinderivater, fremstilling heraf og deres anvendelse som lægemidler
NO20101069L (no) Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva
HUP0400365A2 (hu) 3-Fluor-pirrolidinek, mint cukorbetegség elleni szerek és a vegyületeket tartalmazó gyógyszerkészítmények
DK0635015T3 (da) Acylaminoindolderivater som 5-Htl agonister
EE9700282A (et) Bensimidasooli ühendid, nimetatud ühendeid sisaldavad farmatseutilised kompositsioonid ja nende kasutamine
SE9603283D0 (sv) New compounds
FI945581A (sv) Substituerade (arylalkoxibensyl) aminopropanamidderivat, deras framställning och användning som antiepileptiska, neuroprotektiva och antidepressiva medel
PE20001234A1 (es) Compuestos azabiciclicos sustituidos de heteroaril-aminoetil/benzisoxazol como antagonistas serotonergicos 5-ht1
SE9804126D0 (sv) New pharmaceutical composition
SE9703374D0 (sv) A new combination
FI945582A0 (sv) Substituerade (arylalkylaminobensyl) aminopropionamidderivat, deras frmaställning och användning som antiepileptiska, neuroprotektiva och antidepressiva medel
FI940568A0 (sv) Oxindol-1-(N-(alkoxikarbonyl))karboxiamider och 1-N-karboxamido)karboxamider som antiinflammatoriska medel
SE9702534D0 (sv) Compounds
TW429147B (en) Pharmaceutical composition for the treatment of CNS disorders
HUP0202237A2 (hu) Amin, módosított pszeudomicin vegyületek, azokat tartalmazó gyógyászati készítmény és alkalmazásuk
DK0667860T3 (da) Azaspiroalkan-derivater som terapeutiske midler